JPMorgan Reinstates Alnylam Pharmaceuticals (ALNY) at Overweight
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $312.78 +3.68%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Overweight rating and a price target of $420.00.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $294.30 yesterday.
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- Alliance Global Partners Starts Marti Technologies (MRT) at Buy
- Deutsche Bank Resumes Kloeckner & Co SE (KCO:GR) at Hold
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
